Gynecologic Cancers Features Archive
Telephone interviews to deliver genetic counseling may be non-inferior to in-person counseling.
Data sharing and increased pools of data are promising for prevention and early diagnosis of breast cancer and ovarian cancer.
New guidelines provide clinical practice recommendations for patients with cervical cancer in regions with "basic, limited, enhanced, and maximal" health care resources.
Study results show that women who carry a BRCA1 mutation have a shorter reproductive lifespan than noncarriers.
Farletuzumab, did not meet its primary endpoint in first platinum-sensitive relapse of ovarian cancer. But in a subset of patients, risk of progression was significantly reduced.
The decade-long paradigm shift in decoding ovarian cancer is only now beginning to make its way from research journals into clinical practice.
Not only may co-testing help detect more cases of invasive cervical cancer, but it also may lower overall health care costs.
New guidelines stated that screening with an FDA-approved primary HPV test could substitute cytology-based cervical cancer screening methods.
By identifying patients with cervical cancer as low, intermediate, or high-risk, physicians can determine whether bevacizumab will provide survival benefit.
Ovarian cancer may progress more slowly in women who once used oral contraceptives (OCs).
Pre- or postmenopausal women with epithelial ovarian cancer can safely be treated with adjuvant hormone therapy.
A retrospective study showed improved survival among patients with ovarian cancer treated with beta-blockers.
Multigene panel testing can identify mutations that warrant management changes in patients who lack BRCA1 and 2.
Treatment of ovarian cancer with IP chemo resulted in significant improvement in survival, but benefit could be explained by clinical factors.
Newly validated nomograms were more prognostic of patient survival from cervical cancer than cancer stage.
[Biomark Cancer] Biomarkers can provide great opportunities in the management of the most common HIV-associated malignancies, namely, Kaposi sarcoma, non-Hodgkin's lymphoma, and invasive cervical cancer.
A review of data suggests that HPV testing alone every 3 years provides a high level of reassurance against cervical cancer.
Rate of cervical cancer in African-American women is higher than what was previously recognized.
New colorectal cancer surveillance strategies are warranted in cervical cancer survivors who have been treated with radiotherapy.
The PARP inhibitor veliparib shows promise in women with BRCA-mutated gynecologic cancers that have not responded to previous treatments.
For women with a BRCA mutation, delaying oophorectomy beyond age 35 sharply increases the risk of cancer and mortality.
Research has revealed new genetic variants in patients with ovarian cancer that may eventually help detect the disease earlier.
Patients given bevacizumab survived almost 4 months longer than controls, but had a higher rate of adverse events.
Researchers have discovered a novel approach to making ovarian tumor cells more visible to anticancer therapy.
Great strides have been made in cancer research this year, including targeted therapies that may soon be used as a standard of care.
A new study reveals that the HPV vaccine generates longer-term immune responses than previously thought.
Emerging screening technologies and strategies are being added to the cervical cancer prevention arsenal.
New cancer therapies and statins demonstrate efficacy in treating and perhaps even preventing ovarian cancer recurrence.
A preliminary study finds that rising serum calcium levels may detect ovarian cancer at a preclinical stage.
Screening healthy women for ovarian cancer may do more harm than good, but is it a risk some patients may be willing to take for peace of mind?
Improved screening practices, preventative immunizations, and timely treatment of invasive disease can help reduce the number of deaths due to cervical cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Evidence Grows Linking BIA-ALCL to Textured Surface of Some Breast Implants
- Could Cytostatic Drugs Unleash Antitumor Immunity in Lung Cancer?
- Primary End Point Not Met in Trial Testing Nivolumab Monotherapy for DLBCL
- Increased Risk of Myeloma in African Americans Driven By Higher Rates of 3 Disease Subtypes
- Fermented Dairy and Cancer
- In Mice, Lithium Shown to Reverse Dysfunction Related to Brain Tumor Compression
- Fermented Dairy and Cancer
- Immunotherapy Plus Chemotherapy May Turn Cold Tumors Hot
- Spending on Medical DTC Advertising Increased Dramatically Over the Past 20 Years
- SURTIME Trial: Surgery May Not Be Most Appropriate Frontline Treatment in mRCC